α1-Antitrypsin (A1AT) purified from human plasma upregulates expression and release of angiopoietin-like protein 4 (Angptl4) in adherent human blood monocytes and in human lung microvascular endothelial cells, providing a mechanism for the broad immune-regulatory properties of A1AT independent of its antiprotease activity. In this study, we demonstrate that A1AT (Prolastin), a potent inducer of Angptl4, contains significant quantities of the fatty acids (FA) linoleic acid (C18:2) and oleic acid (C18:1). However, only trace amounts of FAs were present in preparations that failed to increase Angplt4 expression, for example, A1AT (Zemaira) or M-type A1AT purified by affinity chromatography. FA pull-down assays with Western blot analysis revealed a FA-binding ability of A1AT. In human blood-adherent monocytes, A1AT-FA conjugates upregulated expression of Angptl4 (54.9-fold, p < 0.001), FA-binding protein 4 (FABP4) (11.4-fold, p < 0.001), and, to a lesser degree, FA translocase (CD36) (3.1-fold, p < 0.001) relative to A1AT devoid of FA (A1AT-0). These latter effects of A1AT-FA were blocked by inhibitors of peroxisome proliferator-activated receptor (PPAR) β/δ (ST247) and PPARγ (GW9662). When compared with controls, cell pretreatment with ST247 diminished the effect of A1AT-LA on Angptl4 mRNA (11.6- versus 4.1-fold, p < 0.001) and FABP4 mRNA (5.4- versus 2.8-fold, p < 0.001). Similarly, preincubation of cells with GW9662 inhibited inducing effect of A1AT-LA on Angptl4 mRNA (by 2-fold, p < 0.001) and FABP4 mRNA (by 3-fold, p < 0.001). Thus, A1AT binds to FA, and it is this form of A1AT that induces Angptl4 and FABP4 expression via a PPAR-dependent pathway. These findings provide a mechanism for the unexplored area of A1AT biology independent of its antiprotease properties.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232844 | PMC |
http://dx.doi.org/10.4049/jimmunol.1500740 | DOI Listing |
Sci Rep
January 2025
Department of Trauma Surgery, Hannover Medical School, Carl-Neuberg St. 1, 30625, Hannover, Lower Saxony, Germany.
Treatment of severely injured patients represents a major challenge, in part due to the unpredictable risk of major adverse events, including death. Preemptive personalized treatment aimed at preventing these events is a crucial objective of patient management; however, the currently available scoring systems provide only moderate guidance. Biomarkers from proteomics/peptidomics studies hold promise for improving the current situation, ultimately enabling precision medicine based on individual molecular profiles.
View Article and Find Full Text PDFWiad Lek
December 2024
UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE.
Objective: Aim: To determine the main clinical and laboratory features and severity of colon dysbiosis in irritable bowel syndrome (IBS) and IBD in patients with NAFLD.
Patients And Methods: Materials and Methods: 80 patients with NAFLD were examined. Patients were divided into two groups.
Wiad Lek
December 2024
UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE.
Objective: Aim: To study the characteristics of barrier function impairments of the large intestine in patients with UC and concomitant joint damage.
Patients And Methods: Materials and Methods: At the clinical base of the Department of Therapy and Family Medicine, 80 patients with inflammatory bowel disease (IBD) were examined. Patients with IBD were divided into two groups.
Biochimie
November 2024
Laboratoire de Biochimie « Hormonologie, Métabolisme, Nutrition & Oncologie », CHU, F-59037 Lille, France; Univ. Lille ULR 4483 - IMPECS, Institut Pasteur Lille, F-59000 Lille, France.
Alpha-1 antitrypsin (A1AT) is the major circulating serine protease inhibitor. Hypersialylated glycoforms (HSG) are produced to boost A1AT anti-inflammatory and anti-protease properties. Their occurrence and prognostic impact outside severe COVID-19 or community-acquired pneumonia are unknown.
View Article and Find Full Text PDFClinics (Sao Paulo)
November 2024
Rheumatology Division, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HCFMUSP), São Paulo, SP, Brazil.
Background: Alpha-1-Antitrypsin (A1AT) is a protease inhibitor encoded by the SERPINA1 gene. A1AT serves as the primary natural inhibitor of Proteinase 3 (PR3), an enzyme found in neutrophils. PR3 is an antigenic target of Anti-Neutrophil Cytoplasmic Antibodies (ANCA).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!